WVE-007: Silencing a Fat-Storage Gene to Lose Fat Without Losing Muscle (July 29, 2026)
Table of Contents
A different kind of obesity drug
Almost every weight-loss medicine making headlines - semaglutide, tirzepatide, retatrutide, the amylin analogs - works by turning down appetite. WVE-007, from Wave Life Sciences, takes a different route entirely. It is a small interfering RNA (siRNA) that goes into the liver and silences a single gene, INHBE, in order to change how fat tissue stores and releases energy. Instead of making you eat less, it aims to make your fat cells burn more - and, importantly, to do so while sparing muscle. That last point is why the program has drawn outsized attention in 2026.
The genetics that started it
The idea did not come from a screen; it came from people. Large human genetic studies found that individuals born with rare loss-of-function variants in INHBE - the gene encoding the liver hormone (hepatokine) Activin E - carry a lower waist-to-hip ratio and a healthier metabolic profile: less abdominal fat, lower triglycerides, higher HDL and a reduced risk of type 2 diabetes, apparently without a downside. Variants that knock out ALK7 (the ACVR1C receptor Activin E signals through) show the same protective pattern. In other words, nature has already run the experiment, and 'less Activin E signaling' looks like a good place to be. WVE-007 is an attempt to reproduce that lucky genotype with a drug.
How WVE-007 works
Activin E is secreted by the liver and acts on fat cells through the ALK7 receptor, where it suppresses lipolysis - the breakdown of stored fat - and encourages fat storage. WVE-007 is a GalNAc-conjugated siRNA, a format that homes to the liver and degrades a target messenger RNA; here it silences INHBE, lowering the amount of Activin E the body makes. With less Activin E reaching ALK7, the brake on fat mobilization is released and adipose tissue shifts toward burning fat. Because the mechanism sits in fat metabolism rather than appetite, the hope is that the weight that comes off is disproportionately fat, leaving lean mass intact.
What the INLIGHT trial has shown
Wave is testing WVE-007 in the Phase 1 INLIGHT trial. In December 2025 the company reported that a single 240 mg subcutaneous dose improved body composition at three months compared with baseline: visceral fat fell 9.4% (p=0.02), total body fat fell 4.5% - about 3.5 pounds (p=0.07) - and lean mass rose 3.2%, roughly 4.0 pounds (p=0.01). Wave framed the fat loss as similar to what GLP-1 drugs deliver at three months, but without the muscle loss that often accompanies incretin therapy. In March 2026 six-month interim data showed the effect deepening on a placebo-adjusted basis: visceral fat down about 14% (p<0.05), total fat down about 5%, waist circumference down about 3% and body weight down about 1%, with lean mass stabilized (about +2%). Reductions in serum Activin E were durable, which is what raised the striking possibility of once- or twice-yearly dosing.
Why the muscle-sparing angle matters
One of the loudest critiques of GLP-1-based weight loss is that a meaningful share of the pounds lost is lean mass, not just fat - a concern for older patients and anyone worried about strength and metabolic health. A wave of next-generation programs is being pitched partly on improving the 'quality' of weight loss: myostatin and activin-pathway agents such as bimagrumab, trevogrumab and taldefgrobep, muscle-sparing incretin designs like MariTide, and now adipose-directed genetic approaches like WVE-007. What makes WVE-007 distinctive is that preserving - or even adding - lean mass appears to fall out of its mechanism rather than being bolted on. If that holds up, it could be used on its own or stacked on top of an incretin to shift the fat-to-muscle ratio of the weight someone loses.
The pathway and the players
WVE-007 is the most clinically advanced entrant in what is quickly becoming a crowded lane. Arrowhead Pharmaceuticals is developing its own RNAi therapeutics against the same biology - ARO-INHBE (Activin E) and ARO-ALK7 (the receptor) - and has reported that silencing the pathway improves body composition, including combination data where an INHBE knockdown roughly doubled weight loss on top of tirzepatide. That convergence of independent programs on the Activin E/ALK7 axis, all pointing back to the same human genetics, is a big part of why the field takes the target seriously.
The honest caveats
This is still early. INLIGHT is a Phase 1 trial reporting interim results, and the headline weight loss so far is modest - around 1% at six months - because the story is about composition, not the scale. Whether fat-selective, muscle-sparing change translates into the kind of outcomes regulators and patients want will take larger, longer studies; Wave began the Phase 2a portion of INLIGHT in people with higher BMI and comorbidities in the second quarter of 2026, with an eye toward obesity, MASH, type 2 diabetes and cardiovascular disease. The long-term consequences of durably lowering Activin E in humans are not yet known. WVE-007 is a genetically grounded, mechanistically fresh bet on the next phase of obesity medicine - one to watch as it moves through the clinic, not a proven therapy. It is an investigational biologic, not a supplement or research chemical, and any 'WVE-007' or 'INHBE siRNA' offered for sale is unverified.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Wave Life Sciences - Positive Interim Phase 1 INLIGHT Data at Six Months for WVE-007 (Mar 26, 2026) Source
- [2] Wave Life Sciences - Positive Interim Phase 1 INLIGHT Data at Three Months for WVE-007 (Dec 8, 2025) Source
- [3] Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity (Nature Communications, 2022) Source
Related Articles
EASL 2026 names pemvidutide IMPACT data Best of Congress with 68.6% qFibrosis regression, the BELIEVE trial in Nature Medicine shows bimagrumab + semaglutide achieves 22.1% weight loss with 92% from fat, retatrutide TRIUMPH-1 sets 28.3% weight loss record and NDA filing on track for Q4 2026, Biohaven's taldefgrobep completes Phase 2 enrollment for muscle-preserving obesity treatment, and FDA's GLP-1 compounding exclusion comment period closes June 29.
Apitegromab (SRK-015): The First Muscle-Targeted Myostatin Antibody to Win a Phase 3 - in SMA, and Now Obesity (July 14, 2026)
For two decades, drugging myostatin - the body's brake on muscle growth - was a graveyard of failed trials. Apitegromab changed that. Scholar Rock's antibody binds only the inactive precursor forms of myostatin, and in the Phase 3 SAPPHIRE trial it became the first muscle-targeted therapy to improve motor function in spinal muscular atrophy on top of SMN drugs. Now the same mechanism is showing up in obesity: in Phase 2 EMBRAZE, apitegromab preserved ~55% more lean mass during tirzepatide weight loss. Here is how it works, what the data show, and where its September 30, 2026 FDA decision stands.
Trevogrumab: Regeneron's Myostatin Antibody Aims to Keep the Muscle On During GLP-1 Weight Loss (July 16, 2026)
GLP-1 drugs melt away fat - but about a third of the weight lost is muscle. Regeneron's anti-myostatin antibody trevogrumab (REGN1033) is designed to fix that. In the Phase 2 COURAGE trial, adding it to semaglutide halved lean-mass loss, and a triplet with garetosmab preserved over 80% of muscle while deepening fat loss. Here's where it fits in the muscle-preservation race.